Gapping up
In reaction to strong earnings/guidance:
- TGI +19.1%, SMTC +12.5%, TOL +9.8%, DLTR +7.9%, LL +6.1%, SPTN +5.2%, WDAY +5.1%, CSIQ +3.7%, TPX +2.4%, SAFM +1.3%, SHOO +0.9%
Other news:
- PHAS +54.5% (receives FDA clearance to launch trial evaluating PB1046 as a treatment for hospitalized COVID-19 patients)
- TGI +19.2% (selected as supplier of hydraulic components for new Bell 360 Invictus Attack aircraft)
- HPP +14.4% (to join the S&P MidCap 400)
- CERC +13.6% (receives FDA clearance to proceed with a proof-of-concept clinical trial of its anti-LIGHT monoclonal antibody CERC-002 in patients with COVID-19 cytokine storm induced Acute Respiratory Distress Syndrome)
- AOBC +10% (to change name to Smith & Wesson Brands, effective June 1; to trade under ticker symbol "SWBI")
- SLP +9.5% (to join the S&P SmallCap 600)
- GAN +8.3% (Cordish Gaming Group has engaged GAN as their enterprise software Platform provider)
- PLMR +8% (to join the S&P SmallCap 600)
- DHC +5.6% (to join the S&P SmallCap 600)
- BA +4.9% (resumes production of 737 MAX program)
- MRNA +4.8% (Moderna and CordenPharma extend strategic manufacturing services agreement for the supply of lipid excipients to be used in Moderna's vaccine against the novel coronavirus SARS-CoV-2)
- LOGI +3.1% (approves a new, three-year share buyback program, which authorizes the co to use up to $250 mln to repurchase its shares; raises dividend)
- ZLAB +2.3% (announces positive topline results from the Phase 3 NORA study study of ZEJULA as a maintenance therapy in Chinese patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer)
- BYD +1.4% (to resume operations at 13 properties)
- GSK +1.1% (intends to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations)
Analyst comments:
- ALLY +2.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- QCOM +1.3% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)